The clinical trials targeting Trop2 ADC in SCLC are currently underway; phase I and II data showed that, for recurrent SCLC, ORR is 30%–40%, PFS is around 4 months, and the preliminary OS is 13.6 months with manageable safety profile, so that Trop2 ADC is worthy further research in SCLC (188, 189). Here, TACSTD2 is linked to small cell lung carcinoma.